 VALENCIA, Calif., Nov. 10, 2020 GLOBE NEWSWIRE -- AVITA Therapeutics, Inc. NASDAQ: RCEL, ASX:AVH, a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its fiscal first quarter of 2021, ended September 30, 2020. 